Vertebrogenic Radiculopathy L5, S1 Clinical Trial
Official title:
Open Randomised Comparative Study of the Efficacy and Safety of Neuromultivit (Solution for Injections, 2 ml) in Patients With Vertebrogenic Radiculopathy
The purpose of the study is to assess the efficacy and safety of Neuromultivit (solution for injections) in treatment of vertebrogenic radiculopathy L5, S1 in comparison with standard therapy. The patients are randomised into two groups: standard therapy group and standard therapy plus Neuromultivit group.
Group 1 (50 patients) receive Neuromultivit (2 ml per day, i.m.) for 7 days, then
-Neuromultivit (2 ml per day, i.m.) every other day for 10 days and standard therapy for 20
days.
Group 2 (50 patients) receive only standard therapy for 20 days.
Standard therapy involves:
- Voltaren (100 mg prolonged-released film-coated tablets once daily) for 20 days
- Sirdalud (2 mg tablets three times a day) for 20 days
;